Clinical Cancer Research, Vol 4, Issue 2 419-428, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma

RA Ghossein, D Coit, M Brennan, ZF Zhang, Y Wang, S Bhattacharya, A Houghton and J Rosai
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

The objectives of this study were to evaluate the prognostic significance of reverse transcription PCR (RT-PCR) detection of tyrosinase mRNA in the peripheral blood (PB) and bone marrow (BM) of patients with stage II-IV malignant melanoma (MM). Seventy-three PB samples and 109 BM aspirates from 123 assessable patients with stage II-IV MM were analyzed for tyrosinase mRNA using nested RT-PCR. Twenty-five controls without MM were also evaluated. The RT-PCR results were correlated with overall survival (OS) and clinical stage. Overall, 23 of the 123 patients with MM (19%) had tyrosinase mRNA in their blood and/or BM. RT-PCR positivity was present in the PB of 9 of 73 patients (12%), whereas 18 of 109 (16.5%) had tyrosinase mRNA in their BM. All controls were tyrosinase PCR negative. There was no correlation between RT-PCR results and clinical stage. Within stage II, BM PCR-positive patients had a shorter median survival (24 months) than BM PCR-negative individuals (median not reached), with a P approaching significance (P = 0.06). There was a statistically significant correlation between blood PCR positivity and decreased overall survival (P = 0.03) in all patients. Blood PCR positivity was associated with a significantly decreased OS in stage II and III (P = 0.01 and 0.02, respectively) and was not a predictor of OS in stage IV. In multivariate analysis, blood RT-PCR for tyrosinase mRNA was found to be an independent predictor of survival (P = 0.03; risk ratio, 2.87). RT-PCR can specifically detect tyrosinase mRNA in the PB and BM of patients with MM. Blood RT-PCR is an independent predictor of overall survival in stage II-III MM. Additional studies are needed to define the potential role of this assay in the management of patients with advanced melanoma.

This article has been cited by other articles:

				R. Schuster, N. E. Bechrakis, A. Stroux, A. Busse, A. Schmittel, C. Scheibenbogen, E. Thiel, M. H. Foerster, and U. Keilholz Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma Clin. Cancer Res., February 15, 2007; 13(4): 1171 - 1178. [Abstract] [Full Text] [PDF]

				S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis Clin. Cancer Res., August 1, 2006; 12(15): 4605 - 4613. [Abstract] [Full Text] [PDF]

				T. G. Zogakis, R. Essner, H.-j. Wang, R. R. Turner, Y. T. Takasumi, R. L. Gaffney, J. H. Lee, and D. L. Morton Melanoma Recurrence Patterns After Negative Sentinel Lymphadenectomy Arch Surg, September 1, 2005; 140(9): 865 - 872. [Abstract] [Full Text] [PDF]

				C. Voit, M. Kron, J. Rademaker, M. Schwurzer-Voit, W. Sterry, L. Weber, C. Ozdemir, T. Proebstle, and U. Keilholz Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival J. Clin. Oncol., February 20, 2005; 23(6): 1218 - 1227. [Abstract] [Full Text] [PDF]

				R. Wlodzimierz, P. Rutkowski, Z. I. Nowecki, J. Kulik, A. Nasierowska-Guttmejer, and J. A. Siedlecki Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay Ann. Surg. Oncol., November 1, 2004; 11(11): 988 - 997. [Abstract] [Full Text] [PDF]

				U. S. Kammula, R. Ghossein, S. Bhattacharya, and D. G. Coit Serial Follow-Up and the Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction--Staged Sentinel Lymph Nodes From Melanoma Patients J. Clin. Oncol., October 1, 2004; 22(19): 3989 - 3996. [Abstract] [Full Text] [PDF]

				U. Keilholz, P. Goldin-Lang, N. E. Bechrakis, N. Max, A. Letsch, A. Schmittel, C. Scheibenbogen, K. Heufelder, A. Eggermont, and E. Thiel Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Clin. Cancer Res., March 1, 2004; 10(5): 1605 - 1612. [Abstract] [Full Text] [PDF]

				A. Letsch, U. Keilholz, G. Assfalg, V. Mailander, E. Thiel, and C. Scheibenbogen Bone Marrow Contains Melanoma-reactive CD8+ Effector T Cells and, Compared with Peripheral Blood, Enriched Numbers of Melanoma-reactive CD8+ Memory T Cells Cancer Res., September 1, 2003; 63(17): 5582 - 5586. [Abstract] [Full Text] [PDF]

				J. Szenajch, B. Jasinski, A. Synowiec, J. Kulik, M. Chomicka, J. Struzyna, Z. Nowecki, P. Rutkowski, W. Ruka, W. Kupsc, et al. Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma Clin. Chem., September 1, 2003; 49(9): 1450 - 1457. [Abstract] [Full Text] [PDF]

				G. Schleiermacher, M. Peter, O. Oberlin, T. Philip, H. Rubie, F. Mechinaud, D. Sommelet-Olive, J. Landman-Parker, D. Bours, J. Michon, et al. Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor J. Clin. Oncol., January 1, 2003; 21(1): 85 - 91. [Abstract] [Full Text] [PDF]

				R. J. Feezor, E. M. Copeland III, and S. N. Hochwald Significance of Micrometastases in Colorectal Cancer Ann. Surg. Oncol., December 1, 2002; 9(10): 944 - 953. [Full Text] [PDF]

				B. Mellado, M. del Carmen Vela, D. Colomer, L. Gutierrez, T. Castel, L. Quinto, M. Fontanillas, N. Reguart, J. M. Domingo-Domenech, C. Montagut, et al. Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon J. Clin. Oncol., October 1, 2002; 20(19): 4032 - 4039. [Abstract] [Full Text] [PDF]

				T. E. Godfrey, S. Raja, S. D. Finkelstein, W. E. Gooding, L. A. Kelly, and J. D. Luketich Prognostic Value of Quantitative Reverse Transcription-Polymerase Chain Reaction in Lymph Node-negative Esophageal Cancer Patients Clin. Cancer Res., December 1, 2001; 7(12): 4041 - 4048. [Abstract] [Full Text] [PDF]

				I. Y. Cheung and N.-K. V. Cheung Quantitation of Marrow Disease in Neuroblastoma by Real-Time Reverse Transcription-PCR Clin. Cancer Res., June 1, 2001; 7(6): 1698 - 1705. [Abstract] [Full Text] [PDF]

				U. Reinhold, C. Berkin, A.-K. Bosserhoff, A. Deutschmann, C. Garbe, R. Glaser, R. Hein, G. Krahn, R. U. Peter, G. Rappl, et al. Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction-Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group J. Clin. Oncol., March 15, 2001; 19(6): 1723 - 1727. [Abstract] [Full Text] [PDF]

				H. Tsao, U. Nadiminti, A. J. Sober, and M. Bigby A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma Arch Dermatol, March 1, 2001; 137(3): 325 - 330. [Abstract] [Full Text] [PDF]

				U. Trefzer, C. Schlegel, W. Sterry, E. Spath-Schwalbe, K. Possinger, and C. Denkert Fulminant Intravascular Disseminating Malignant Melanoma Mimicking Acute Leukemia Blood, August 15, 1999; 94(4): 1483 - 1484. [Full Text] [PDF]

				B. J. Curry, K. Myers, and P. Hersey MART-1 Is Expressed Less Frequently on Circulating Melanoma Cells in Patients Who Develop Distant Compared With Locoregional Metastases J. Clin. Oncol., August 1, 1999; 17(8): 2562 - 2562. [Abstract] [Full Text] [PDF]

				R. A. Ghossein, S. Bhattacharya, and J. Rosai Molecular Detection of Micrometastases and Circulating Tumor Cells in Solid Tumors Clin. Cancer Res., August 1, 1999; 5(8): 1950 - 1960. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, N.-K. V. Cheung, R. A. Ghossein, J. M. Satagopan, S. Bhattacharya, and D. G. Coit Association between Molecular Detection of GAGE and Survival in Patients with Malignant Melanoma: A Retrospective Cohort Study Clin. Cancer Res., August 1, 1999; 5(8): 2042 - 2047. [Abstract] [Full Text] [PDF]

				B. Mellado, L. Gutierrez, T. Castel, D. Colomer, M. Fontanillas, J. Castro, and J. Estape Prognostic Significance of the Detection of Circulating Malignant Cells by Reverse Transcriptase-Polymerase Chain Reaction in Long-Term Clinically Disease-free Melanoma Patients Clin. Cancer Res., July 1, 1999; 5(7): 1843 - 1848. [Abstract] [Full Text] [PDF]

				M. Muhlbauer, N. Langenbach, W. Stolz, R. Hein, M. Landthaler, R. Buettner, and A.-K. Bosserhoff Detection of Melanoma Cells in the Blood of Melanoma Patients by Melanoma-inhibitory Activity (MIA) Reverse Transcription-PCR Clin. Cancer Res., May 1, 1999; 5(5): 1099 - 1105. [Abstract] [Full Text] [PDF]